title: [Regulating action of iron regulatory protein-2 in iron metabolism of lung cancer].
abstract: OBJECTIVE
  To discuss the regulating mechanism of iron regulatory protein-2 (IRP2) in the iron metabolism of lung cancer.
  
  
  METHODS
  The cultured A549 cells were divided into 3 groups: liposome group (including liposomes 20 mg/L), random oligonucleotide group (SCODN group) and antisense oligonucleotide group (ASODN group). And the liposome-mediated transfection was employed with the liposome and SCODN groups as controls. Reverse transcription-polymerase chain reaction (RT-PCR) and Western blot were used to examine the mRNA and protein expressions of iron metabolism-related transferring (Tf), transferrin receptor (TfR) and ferritin (Fn) genes, etc.
  
  
  RESULTS
  After a 48-hour transfection, the mRNA expression of Tf had no statistically significant difference among three groups (F = 2.18, P = 0.078); the mRNA expression of TfR in the ASODN group was significantly lower than that in the liposome and SCODN groups (P < 0.05). The expression of Fn mRNA in the ASODN group (0.56 ± 0.06) was higher than that in the liposome (0.36 ± 0.05) and SCODN groups (0.39 ± 0.03) (P < 0.05). After a 48-hour transfection, the IRP2 protein expression of the ASODN group was significantly lower than those of the liposome and SCODN groups (P < 0.05). The Tf protein expression was not statistically different in three groups (F = 2.67, P = 0.088). The TfR protein expression of the ASODN group was lower than those of the liposome and SCODN groups (P < 0.05). And the Fn protein expression of the ASODN group was higher than those of the liposome and SCODN groups (P < 0.05).
  
  
  CONCLUSIONS
  IRP2 may affect the expressions of TfR and Fn in lung adenocarcinoma A549 cells by changing the amount of protein and regulating the iron metabolism.
authors.affiliation: Department of Respiratory Medicine, Zhengzhou University, Zhengzhou, China. chengzhehi@126.com
authors.forename: Zhe
authors.initials: Z
authors.lastname: Cheng
authors.forename: Yu-feng
authors.initials: YF
authors.lastname: Liu
authors.forename: Yong-na
authors.initials: YN
authors.lastname: Song
authors.forename: Ling-ling
authors.initials: LL
authors.lastname: Dai
authors.forename: Yan
authors.initials: Y
authors.lastname: Kang
authors.forename: Jie
authors.initials: J
authors.lastname: Xia
authors.forename: Ji-ming
authors.initials: JM
authors.lastname: Si
authors.forename: Chun-yan
authors.initials: CY
authors.lastname: Chen
mesh_terms: D000230:Adenocarcinoma / Q000378:metabolism*; D000077192:Adenocarcinoma of Lung; D045744:Cell Line, Tumor; D005293:Ferritins / Q000378:metabolism; D006801:Humans; D007501:Iron / Q000378:metabolism*; D035942:Iron Regulatory Protein 2 / Q000235:genetics / Q000378:metabolism*; D008081:Liposomes / Q000008:administration & dosage; D008175:Lung Neoplasms / Q000378:metabolism*; D020319:Oligodeoxyribonucleotides, Antisense / Q000235:genetics; D011990:Receptors, Transferrin / Q000378:metabolism
chemical_list: D008081:Liposomes; D020319:Oligodeoxyribonucleotides, Antisense; D011990:Receptors, Transferrin; D005293:Ferritins; D007501:Iron; C546174:IREB2 protein, human; D035942:Iron Regulatory Protein 2